证券代码：688710 证券简称：益诺思 公告编号：2025-025 上海益诺思生物技术股份有限公司 关于首次公开发行前已发行股份及首次公开发行战略 配售股份上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发战略配售股份（限售期 12 月）；股票认购方式 为网下，上市股数为3,524,490股。 ? 除首发配售股份外，其他股票上市类型为首发限售股份；股票认购方式为 网下，上市股数为58,973,550股。 三、 本次上市流通的限售股的有关承诺 （一）股东上海张江生物医药基地开发有限公司、上海翱鹏企业管理中心（有 限合伙）作出限售安排、自愿锁定、持股及减持意向的承诺如下： ? 本次股票上市流通总数为62,498,040股。 ? 本次股票上市流通日期为2025 年 9 月 3 日。 一、 本次上市流通的限售股类型 二、 本次上市流通的限售股形成后至今公司股本数量变化情况 本次上市流通的限售股属于首次公开发行前已发行的部分股份及首次公开发 行战略配售股，自公司首次公开发行至 ...

上海益诺思生物技术股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688710 证券简称：益诺思 公告编号：2025-024 重要内容提示： 会议问题征集：投资者可于 2025 年 9 月 1 日(星期一)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 bo@innostar.cn 进行会前提问，公司将在本次说明会上对投资者普遍 关注的问题进行回答。 上海益诺思生物技术股份有限公司（以下简称"公司"）拟于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资者更全面 深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 9 月 2 日（星期二）16:00-17:00 举行 2025 年半年度业绩说明会， 就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半 年度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 ...

Core Insights - Yinosh experienced a slight decline of 0.31% on August 22, with a trading volume of 55.43 million yuan [1] - The company reported a financing buy-in amount of 10.08 million yuan and a net financing buy of 0.61 million yuan on the same day [1] - As of August 22, the total financing and securities lending balance for Yinosh was 92.67 million yuan, accounting for 7.84% of its market capitalization [1] Financing and Securities Lending - On August 22, Yinosh had a financing buy-in of 10.08 million yuan, with a financing balance of 92.67 million yuan [1] - The company had no securities lending transactions on that day, with a remaining balance of 0.00 shares [1] Company Overview - Shanghai Yinosh Biotechnology Co., Ltd. was established on May 12, 2010, and is located in the China (Shanghai) Pilot Free Trade Zone [1] - The company specializes in providing comprehensive research and development services (CRO) primarily focused on non-clinical research in biomedicine, with 95.42% of its revenue coming from non-clinical services [1] - As of March 31, the number of shareholders was 5,435, a decrease of 46.05%, while the average circulating shares per person increased by 97.22% to 5,187 shares [1] Financial Performance - For the period from January to March 2025, Yinosh reported a revenue of 209 million yuan and a net profit attributable to shareholders of 5.52 million yuan, reflecting a year-on-year decrease of 90.30% [1] - Since its A-share listing, Yinosh has distributed a total of 45.11 million yuan in dividends [2] Institutional Holdings - As of March 31, 2025, the top ten circulating shareholders included notable institutional investors such as Agricultural Bank of China Medical Health Stock and China Europe Medical Health Mixed Fund, with varying increases in their holdings [2]

Summary of the Conference Call for Yinos Company Overview - Yinos is positioned as the innovation technology source for China National Pharmaceutical Group, benefiting from internal business cooperation within the group [2][7] - The company has a strategic reserve of experimental monkey resources, ensuring stable supply of core materials [2][8] - Yinos is one of the few companies in China with GLP certifications from China, OECD, and FDA, indicating strong international service capabilities [2][10] Key Points and Arguments - **Growth from National Pharmaceutical Group**: New orders from clients within the group are expected to grow by 26.3% year-on-year in 2024, highlighting Yinos's strategic position and growth potential [2][7] - **Market Position in Ampoules**: Yinos is a leading player in the domestic ampoule market, with a market share of 6.8% in non-clinical safety evaluation, ranking third [3] - **Revenue from Innovative Drugs**: Over 90% of Yinos's revenue comes from innovative drugs, having assisted in nearly 200 first-in-class drug research services [4] - **CRO Industry Growth**: The global CRO market is expected to grow at a compound annual growth rate (CAGR) of nearly 11% in the coming years, driven by rising R&D costs and the need for cost-effective solutions [12][14] Financial Performance - Despite a challenging CXO industry leading to price wars, Yinos has maintained growth in business volume, with clinical CRO revenue expected to grow by 27.2% in 2024, reaching nearly 50 million yuan [6] Strategic Initiatives - **Resource Stability**: Yinos has established a breeding and feeding facility for experimental monkeys, with a book value of approximately 25 million yuan by the end of 2024 [2][8] - **Management Team**: The management team consists of experienced drug evaluation experts, enhancing the company's service quality [9] Industry Trends - **Impact of Patent Cliffs**: The upcoming patent cliffs are expected to lead to significant revenue losses for multinational pharmaceutical companies, prompting them to seek new innovations through mergers and licensing [13] - **Support for Innovation**: The Chinese government has implemented policies to support the development of innovative drugs, including the reactivation of the STAR Market for unprofitable biotech companies [17][19] Future Outlook - **Market Potential**: The domestic innovative drug market is projected to grow significantly, with the proportion of approved innovative drugs increasing from 0.2% in 2018 to 10.4% in 2024 [16] - **Valuation and Risks**: Yinos is projected to achieve a target price of 51.45 yuan based on a 52x P/E ratio, with risks including industry slowdown, regulatory changes, and raw material price fluctuations [25] Conclusion Yinos is well-positioned for future growth within the pharmaceutical industry, leveraging its strategic partnerships, innovative capabilities, and supportive government policies to capitalize on emerging market opportunities.

Investment Rating - The report gives a "Buy" rating for the company for the first time, with a target price of 51.48 CNY based on a 52x P/E ratio for 2025 [5][8]. Core Insights - The company is a leading player in non-clinical safety evaluation in China, backed by strong resources from its parent company, China National Pharmaceutical Group [12][16]. - The CRO (Contract Research Organization) market is expected to see growth driven by increasing demand for innovative drug development and favorable policies [12][44]. - The company has a comprehensive range of GLP (Good Laboratory Practice) certifications, enabling it to provide international standard services [21][22]. Financial Forecast and Investment Recommendations - The projected EPS for 2025-2027 is 0.99, 1.16, and 1.42 CNY respectively, indicating significant growth potential due to the company's competitive advantages [5]. - Revenue is expected to grow from 1,038 million CNY in 2023 to 1,490 million CNY in 2027, with a CAGR of approximately 14.8% [7]. - The company's net profit is forecasted to increase from 194 million CNY in 2023 to 200 million CNY in 2027, reflecting a strong growth trajectory [7]. Company Overview - The company specializes in innovative drug research outsourcing services and ranks third in the domestic preclinical safety evaluation sector [12][29]. - It has successfully assisted in the research services of nearly 200 innovative drugs, covering a wide range of drug types including small molecules and ADCs (Antibody-Drug Conjugates) [12][31]. Market Trends - The CRO market is anticipated to maintain a double-digit growth rate, with global market size projected to reach 126 billion USD by 2028 [44][47]. - The report highlights a rebound in overseas demand for CRO services and an upward cycle in the domestic market, driven by improved financing conditions and increased willingness of domestic pharmaceutical companies to invest in innovative drug development [12][44].

Core Viewpoint - The article highlights the recent financial activities and market performance of Shanghai Yinos Biotech Co., Ltd., including its financing activities and stock performance trends [1]. Financing Activities - Yinos received a net financing inflow of 18.91 million yuan last week, ranking 412th in the market [1]. - The total financing amount for the week was 123 million yuan, while the repayment amount was 104 million yuan [1]. Market Performance - Over the past 5 days, the main capital outflow from Yinos was 3.33 million yuan, with a price decline of 0.43% [1]. - In the last 10 days, the main capital inflow was 27.64 million yuan, resulting in a price increase of 1.88% [1]. Company Overview - Shanghai Yinos Biotech Co., Ltd. was established in 2010 and is located in Shanghai, primarily engaged in technology promotion and application services [1]. - The company has a registered capital of 1.41 billion yuan and a paid-in capital of 1.06 billion yuan [1]. - The legal representative of the company is Chang Yan [1]. Investment and Intellectual Property - Yinos has invested in 3 external companies and participated in 68 bidding projects [1]. - The company holds 15 trademark registrations and 79 patents, along with 223 administrative licenses [1].

Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on the distribution of radioactive drugs in the body to obtain physiological and pathological information [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear medicine imaging equipment, and radiation therapy devices [2] Development Environment - The Chinese government has been actively promoting the nuclear medicine industry through various policies, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - Local governments, such as in Guangdong and Sichuan, have also introduced plans to accelerate the development of the nuclear medicine sector [6][7] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant advancements in technology and capabilities, transitioning from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Nuclear Industry, East China Pharmaceutical, and Yuanda Medical, with East China Pharmaceutical holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new radioactive drug developments, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in diverse nuclear medicine services [20]

Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on imaging and radiotherapy [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear imaging equipment, and radiotherapy devices [2] Development Environment - The Chinese government has implemented various policies to support the nuclear medicine industry, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - These policies aim to enhance innovation, expand clinical applications, and create new opportunities for related enterprises [6] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant technological advancements, moving from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Dongfang, East Cheng Pharmaceutical, and Yuanda Medical, with East Cheng holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new drug development, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in nuclear medicine services [20]

Core Viewpoint - The CRO leader, Zhaoyan Pharmaceutical, has nearly doubled in value, with a more than 50% increase in July, driven by signs of recovery in the CXO market and successful turnaround due to the value of laboratory monkeys [1][2]. Group 1: Market Recovery Signals - The market has observed a recovery signal in the CXO sector, with Zhaoyan Pharmaceutical successfully turning losses into profits by leveraging the value of laboratory monkeys [2][3]. - The increase in monkey prices is attributed to a tightening supply and recovering demand, indicating a potential new cycle in the market [12][24]. Group 2: Financial Performance - Zhaoyan Pharmaceutical's mid-year performance forecast indicates expected revenue between 630 million to 702 million yuan, a year-on-year decline of approximately 17.3% to 25.2%, but a net profit turnaround with estimates between 50.32 million to 75.49 million yuan, largely driven by biological asset value changes [8][9]. Group 3: Supply and Demand Dynamics - The supply of laboratory monkeys is constrained by long breeding cycles and an aging population, with a significant increase in the proportion of breeding females over 8 years old, leading to a decline in reproductive rates [17][20]. - The current supply of laboratory monkeys is around 25,000 to 28,000 annually, while actual demand approaches 40,000, indicating a significant supply-demand gap [25]. Group 4: Future Outlook - The industry faces challenges in increasing monkey supply due to aging populations and long breeding cycles, with any potential recovery in supply expected to take several years [26][27]. - The interplay between biological cycles and market demand suggests that the industry may be on the brink of a new cycle, but significant hurdles remain in achieving a sustainable supply of laboratory monkeys [32][33].

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 13.30 | -6.60% | 97.13万 | 13.47 乙 | | 688710 | 益诺思 | 42.93 | -4.34% | 2.77万 | 1.21亿 | | 300725 | 药石科技 | 47.25 | -4.08% | 22.57万 | 10.92亿 | | 603456 | 九州药业 | 18.32 | -3.48% | 63.91万 | 11.90亿 | | 603259 | 药明康德 | 93.00 | -3.40% | 89.33万 | 83.98亿 | | 300759 | 康龙化成 | 30.10 | -3.22% | 61.22万 | 18.70亿 | | 688202 | 美迪西 | 61.60 | -2.84% | 7.28万 | 4.55 Z | | 002173 | 创新医疗 | 14.92 | -2.74% | 81.94万 | 12.53亿 | | 002821 | 司 ...